NoneNone
Cancer – (21st June to 22nd July) Daily Horoscope Prediction says, Stay healthy and happy today Do not compromise on love today and ensure you keep your partner happy. The professional life will also be successful. Health and wealth are positive today. Do not let egos hamper the romance. Have a great in terms of work today. You are also prosperous but saving money should be the priority. No major medical issues will also trouble you. Cancer Love Horoscope Today You will make the day special in terms of love. Spend more time with your partner and engage in activities that you both love. Love the person unconditionally and you’ll see the difference in life. Marriage is also on the cards. Plan a weekend filled with adventure. Single natives will come across someone special while traveling, in a classroom, official function, or at a party. Propose today to get a positive response. Married male natives should avoid office romance that may hurt their family life. Cancer Career Horoscope Today Be professional in at office and take up new tasks that will keep you busy. Lawyers, academicians, engineers, managers, accountants, and bankers will have a productive day. Government employees can expect a change in destination. Some team leaders will have problems in tackling politics within the team. However, ensure it does not impact the total output. You can expect a change in role while government employees can have a location change. Entrepreneurs will be happy to take the trade to new locations. Cancer Money Horoscope Today No major monetary issue will cause chaos in life. However, it is wise to be careful about investments. Do not invest a major amount in the stock market. You may pick the first part of the day to clear all pending dues. Continue shopping for electronic items and gold. You will require money for hospital expenditures. Businessmen will see funds through promoters and traders will have good returns. Cancer Health Horoscope Today No major health issues will be there. However, some females will have issues related to skin and teeth today. Seniors should be careful while using the staircase. Do not miss the medication and also be careful while driving. Pregnant females should be careful while traveling or boarding a bus. Minor natives may suffer from bruises while playing but they will not be serious. Cancer Sign Attributes Strength: Intuitive, Practical, Kind, Energetic, Artsy, Dedicated, Benevolent, Caring Weakness: Insatiable, Possessive, Prudish Symbol: Crab Element: Water Body Part: Stomach & Breast Sign Ruler: Moon Lucky Day: Monday Lucky Color: White Lucky Number: 2 Lucky Stone: Pearl Cancer Sign Compatibility Chart Natural affinity: Taurus, Virgo, Scorpio, Pisces Good compatibility: Cancer, Capricorn Fair compatibility: Gemini, Leo, Sagittarius, Aquarius Less compatibility: Aries, Libra By: Dr. J. N. Pandey Vedic Astrology & Vastu Expert Website: www.astrologerjnpandey.com E-mail: djnpandey@gmail.com Phone: 91-9811107060 (WhatsApp Only)
SPCA recommending cruelty charges after seizing 59 dogs, 14 birds from B.C. breederKeith Higgins Jr. scores 22 to lead Lehigh to 87-67 victory over Neumann
PM looks to ‘brighter future’ at Christmas and ‘wishes for peace in Middle East’
Johnson scores 33 as Tennessee Tech knocks off NAIA-member Milligan 95-75None
Kyle Birch, Star Of 'A Strange Loop' And Other London Musicals, Dead At 26SEOUL, South Korea — North Korean leader Kim Jong Un vowed to implement the “toughest” anti-U.S. policy, state media reported Sunday, less than a month before Donald Trump takes office as U.S. president. Trump’s return to the White House raises prospects for high-profile diplomacy with North Korea. During his first term, Trump met Kim three times for talks on the North's nuclear program. Many experts however say a quick resumption of Kim-Trump summitry is unlikely as Trump would first focus on conflicts in Ukraine and the Middle East. North Korea's support for Russia's war against Ukraine also poses a challenge to efforts to revive diplomacy, experts say. During a five-day plenary meeting of the ruling Workers’ Party that ended Friday, Kim called the U.S. “the most reactionary state that regards anti-communism as its invariable state policy.” Kim said that the U.S.-South Korea-Japan security partnership is expanding into “a nuclear military bloc for aggression." “This reality clearly shows to which direction we should advance and what we should do and how,” Kim said, according to the official Korean Central News Agency. It said Kim's speech “clarified the strategy for the toughest anti-U.S. counteraction to be launched aggressively” by North Korea for its long-term national interests and security. KCNA didn't elaborate on the anti-U.S. strategy. But it said Kim set forth tasks to bolster military capability through defense technology advancements and stressed the need to improve the mental toughness of North Korean soldiers. The previous meetings between Trump and Kim had not only put an end to their exchanges of fiery rhetoric and threats of destruction, but they developed personal connections. Trump once famously said he and Kim “fell in love.” But their talks eventually collapsed in 2019, as they wrangled over U.S.-led sanctions on the North. North Korea has since sharply increased the pace of its weapons testing activities to build more reliable nuclear missiles targeting the U.S. and its allies. The U.S. and South Korea have responded by expanding their military bilateral drills and also trilateral ones involving Japan, drawing strong rebukes from the North, which views such U.S.-led exercises as invasion rehearsals. Further complicating efforts to convince North Korea to abandon its nuclear weapons in return for economic and political benefits is its deepening military cooperation with Russia. According to U.S., Ukrainian and South Korean assessments, North Korea has sent more than 10,000 troops and conventional weapons systems to support Moscow's war against Ukraine. There are concerns that Russia could give North Korea advanced weapons technology in return, including help to build more powerful nuclear missiles. Ukrainian President Volodymyr Zelenskyy said last week that 3,000 North Korean troops have been killed and wounded in the fighting in Russia's Kursk region. It was the first significant estimate by Ukraine of North Korean casualties since the North Korean troop deployment to Russia began in October. Russia and China, locked in separate disputes with the U.S., have repeatedly blocked U.S.-led pushes to levy more U.N. sanctions on North Korea despite its repeated missile tests in defiance of U.N. Security Council resolutions. Last month, Kim said that his past negotiations with the United States only confirmed Washington’s “unchangeable” hostility toward his country and described his nuclear buildup as the only way to counter external threats.Race-Obsessed Rep. Jasmine Crockett Is Furious Texas Elected White Congressmen Using 'Black and Brown and Asian Bodies'Opinion editor’s note: Strib Voices publishes a mix of guest commentaries online and in print each day. To contribute, click here . ••• When my son Alec passed away after rationing his insulin, my world shattered. Alec, like many people with diabetes, found himself stuck in a cycle of soaring insulin prices. With insurance, he was paying hundreds of dollars monthly for insulin. Without insurance, the cost of that monthly supply jumped to $1,300. The sky-high price forced Alec to stretch out his doses, and less than a week later, he died from diabetic ketoacidosis. Tragically, Alec wasn’t alone. As I shared his story with local news stations and reached out through social media, I was flooded with responses from others in similar situations — people rationing insulin, resorting to desperate measures to survive. I learned of individuals traveling to Canada or Mexico to buy insulin more affordably or meeting strangers in back alleys to exchange lifesaving supplies. It was a heartbreaking realization: Alec’s death was part of a much larger crisis. When state Sen. Erin Murphy, herself a nurse, heard Alec’s story, she reached out. She wanted to help, and together we discussed the importance of an emergency insulin affordability program that could prevent future deaths due to rationing. In testimony before Minnesota’s Health and Human Services Committee, I shared Alec’s story, and the support was overwhelming. Sen. Michael Howard also stepped forward, motivated to make a difference as he ran for office. Working alongside Gov. Tim Walz, they championed what would become the Alec Smith Insulin Affordability Act, turning a vision into reality. The legislation established the Minnesota Insulin Safety Net Program, which has since provided relief to countless Minnesotans. The program allows individuals in need of insulin to access a 30-day emergency supply through their pharmacy and, more importantly, gives them a path to longer-term assistance. The continuing-need branch of the program allows eligible Minnesotans who cannot afford their insulin on an ongoing basis to receive a 90-day supply for no more than $50. As we approach the new year, the need for this program is particularly high. Individuals with high-deductible health insurance plans may face hundreds of dollars in out-of-pocket costs for their prescribed insulin in the first several months of the year. The Insulin Safety Net Program can be a lifeline, helping them afford insulin before they meet their deductible. Additionally, many Minnesotans are traveling to see loved ones during the holidays and battling extreme weather, creating more possibilities for a vial to be left at home, spoil in excessive cold or shatter while on the go. The urgent-need program offers a life-saving option in potential emergency situations. We’ve made significant strides in Minnesota, but no one should have to cross state lines or choose between survival and financial ruin for a medication they depend on daily. Access to insulin should never be a privilege — it must be a guarantee. We need to honor the life Alec lived and ensure the pain of our loss drives meaningful, lasting change for everyone who relies on insulin. Minnesotans have access to an innovative solution, and it’s up to all of us to ensure the program reaches those who need it most. This holiday season, take a moment to share this vital resource with friends, family and neighbors. Ask if they are familiar with the Insulin Safety Net Program and encourage them to spread the word. Every conversation has the potential to create change and, ultimately, save a life. Together, we can make access to insulin a reality for all. Nicole Smith-Holt lives in the Minneapolis area and is a mother of four. She became a policy advocate for insulin access and affordability after the death of her son Alec in 2017. She serves as a co-chair of the Minnesota Advisory Task Force on Lowering Pharmaceutical Drug Prices and is part of the Founder’s Council for United States of Care.
Bad Axe: Wisconsin wary of rival Minnesota with bowl bid in perilTyler Cowen: The sad decline of the public hangout
Deluxe Corp CEO Barry McCarthy purchases $53,975 in stockSignal Gold Shareholders Overwhelmingly Approve Transaction With NexGold Mining
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. “The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. “With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. “Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company’s Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company’s common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient’s condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company’s business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q (“Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company’s Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the Company’s ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.com
Lamenting the contretemps, International Chess Federation President Arkady Dvorkovich said in a statement Sunday that he'd let World Blitz Championship tournament officials consider allowing “appropriate jeans” with a jacket, and other “elegant minor deviations” from the dress code. He said Carlsen's stand — which culminated in his quitting the tournament Friday — highlighted a need for more discussion “to ensure that our rules and their application reflect the evolving nature of chess as a global and accessible sport.” Carlsen, meanwhile, said in a video posted Sunday on social media that he would play — and wear jeans — in the World Blitz Championship when it begins Monday. “I think the situation was badly mishandled on their side,” the 34-year-old Norwegian grandmaster said. But he added that he loves playing blitz — a fast-paced form of chess — and wanted fans to be able to watch, and that he was encouraged by his discussions with the federation after Friday's showdown. “I think we sort of all want the same thing,” he suggested in the video on his Take Take Take chess app’s YouTube channel. “We want the players to be comfortable, sure, but also relatively presentable.” The events began when Carlsen wore jeans and a sportcoat Friday to the Rapid World Championship, which is separate from but held in conjunction with the blitz event. The chess federation said Friday that longstanding rules prohibit jeans at those tournaments, and players are lodged nearby to make sartorial switch-ups easy if needed. An official fined Carlsen $200 and asked him to change pants, but he refused and wasn't paired for a ninth-round game, the federation said at the time. The organization noted that another grandmaster, Ian Nepomniachtchi, was fined earlier in the day for wearing sports shoes, changed and continued to play. Carlsen has said that he offered to wear something else the next day, but officials were unyielding. He said “it became a bit of a matter of principle,” so he quit the rapid and blitz championships. In the video posted Sunday, he questioned whether he had indeed broken a rule and said changing clothes would have needlessly interrupted his concentration between games. He called the punishment “unbelievably harsh.” “Of course, I could have changed. Obviously, I didn’t want to,” he said, and “I stand by that.”Meet the Newest Stock-Split Stock in the Dow Jones. It Has Soared 910% Since Early Last Year, and It's Still a Buy Right Now, According to Wall StreetChess grandmaster Magnus Carlsen returns to a tournament after a dispute over jeans is resolvedWASHINGTON, Dec 30 — Jimmy Carter, the 100-year-old former US president and Nobel peace laureate who rose from humble beginnings in rural Georgia to lead the nation from 1977 to 1981, has died, his nonprofit foundation said yesterday. Carter had been in hospice care since mid-February 2023 at his home in Plains, Georgia — the same small town where he was born and once ran a peanut farm before becoming governor of the Peach State and running for the White House. Carter died “peacefully” at his home in Plains, “surrounded by his family,” the Carter Center said in a statement. “My father was a hero, not only to me but to everyone who believes in peace, human rights and unselfish love,” Chip Carter, the former president’s son, said in the statement. Carter was the oldest living ex-US leader and the nation’s longest-lived president — an outcome that seemed unlikely back in 2015 when the Southern Democrat revealed he had brain cancer. But the US Navy veteran and fervent Christian repeatedly defied the odds to enjoy a long and fruitful post-presidency, after four years in the Oval Office often seen as disappointing. During his single term, Carter placed a commitment on human rights and social justice, enjoying a strong first two years that included brokering a peace deal between Israel and Egypt dubbed the Camp David Accords. But his administration hit numerous snags — the most serious being the taking of US hostages in Iran and the disastrous failed attempt to rescue the 52 captive Americans in 1980. He also came in for criticism for his handling of an oil crisis. In November of that year, Republican challenger Ronald Reagan clobbered Carter at the polls, relegating the Democrat to just one term. Reagan, a former actor and governor of California, swept into office on a wave of staunch conservatism. Active post-presidency As the years passed, a more nuanced image of Carter emerged — one that took into account his significant post-presidential activities and reassessed his achievements. He founded the Carter Center in 1982 to pursue his vision of world diplomacy, and he was the recipient of the 2002 Nobel Peace Prize for his tireless efforts to promote social and economic justice. He observed numerous elections around the world and emerged as a prominent international mediator, tackling global problems from North Korea to Bosnia. Carter, known for his toothy smile, said basic Christian tenets such as justice and love served as the bedrock of his presidency. He taught Sunday school at Maranatha Baptist, his church in Plains, well into his 90s. In recent years, he had received various hospital treatments, including when he revealed in August 2015 that he had brain cancer and was undergoing radiation. ‘ Leader, statesman and humanitarian ’ Tributes poured in from White House leaders past, present and incoming. Bill Clinton said Carter “worked tirelessly for a better, fairer world,” while Donald Trump said Americans owed the Democrat “a debt of gratitude.” George W. Bush said Carter’s legacy would “inspire Americans for generations,” while Barack Obama said the former leader “taught all of us what it means to live a life of grace, dignity, justice, and service.” “America and the world lost an extraordinary leader, statesman and humanitarian,” current President Joe Biden and his wife Jill said in a statement. “For anyone in search of what it means to live a life of purpose and meaning — the good life — study Jimmy Carter, a man of principle, faith, and humility.” In April 2021, the Bidens met with the Carters at their home in Plains. The White House later released a photo showing the couples smiling together, although only Rosalynn was seen by the press outside, bidding the Bidens farewell while using a walker. Rosalynn, Carter’s wife of 77 years, died on November 19, 2023 at age 96. The former president, who looked frail, poignantly appeared at her memorial service in a wheelchair, with a blanket on his lap bearing their likenesses. Carter is survived by the couple’s four children, three sons and a daughter. — AFP
Former US president Jimmy Carter dies aged 100The NATO Parliamentary Assembly’s resolution on Wednesday calling for Ukraine to be supplied with medium-range missiles — defined by the now-defunct INF Treaty as those with ranges between 1,000 and 5,500 kilometers — is a significant development, though not a final decision by the bloc or any national government. If such a decision is made, the options for providing these missiles to Ukraine remain limited. The only readily available medium-range missile system in the West is the US-made Tomahawk, a weapon that has already been used in various global conflicts. Currently, the only ground-based launcher systems capable of firing these missiles are the Mk 70 and the MRC Typhon, both based on the Mk 41 shipborne launching system, with only minor operational differences between them. But will these systems be transferred to Ukraine? The likely goal of America’s Biden administration needs careful consideration. The aim cannot be to decisively end the war in Ukraine, as the existing stock of Tomahawks is insufficient to achieve that objective. Even with a few dozen Tomahawks potentially being transferred to Kiev, such an action would lead to a significant escalation, likely provoking a strong response from Russia — possibly bringing the US and NATO into direct confrontation with Moscow, especially given the inevitable involvement of US military personnel in deploying these weapons. Some experts speculate that this move is part of a larger strategy by the Biden administration to “complicate matters as much as possible” in an effort to make any future peace talks — particularly those under a potential Trump administration — more difficult to pursue. As an alternative, Washington could consider providing JASSM-ER air-launched missiles, which have a range of about 1,000 kilometers and can be deployed from F-16 fighter jets. However, this too would do little to shift the balance of the conflict. The number of available JASSM-ERs would be far too small to lead to a Ukrainian victory, and their use would again risk escalating the conflict, with unpredictable consequences. Moreover, such a transfer would be impossible without continued US technical support. Do NATO’s leaders understand the risks of such actions? Surely they must. So why push for such a resolution? The NATO Parliamentary Assembly, though influential, is one of the least powerful branches of the alliance. Nonetheless, its actions appear to follow the larger direction set by NATO’s leadership, often without the full weight of strategic consequences being considered.